Infliximab (Remicade) for Crohn's Disease
|405,702 Patients Studied||1,420 Studies (View)|
Definition: Infliximab (INN; trade name Remicade) is a monoclonal antibody against tumour necrosis factor alpha. It is used to treat autoimmune diseases. Remicade is marketed by Centocor Ortho Biotech, Inc. (Centocor) in the USA, Mitsubishi Tanabe Pharma in Japan, Xian Janssen in China, and Schering-Plough (now part of Merck & Co) elsewhere. Infliximab was approved by the U.S. Crohn's disease, also known as regional enteritis, is an inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. It primarily causes abdominal pain, diarrhea (which may be bloody if inflammation is at its worst), vomiting, or weight loss, but may also cause complications outside the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration. (SOURCE: Wikipedia)
Where does Infliximab (Remicade) rank compared to other Crohn's Disease treatments?
Health experts published 996 studies on Azathioprine and Crohn's Disease making Azathioprine the #3 most researched treatment. In research involving Crohn's Disease, experts have concluded that Azathioprine is effective in 82 studies and safe in 16 studies.
Health experts published 355 studies on Adalimumab and Crohn's Disease making Adalimumab the #4 most researched treatment. In research involving Crohn's Disease, experts have concluded that Adalimumab is effective in 72 studies and safe in 39 studies.
What peer treatments do patients prefer?
What does the FDA say about side effects?
Most Researched Conditions
What other conditions have been studied?
Most Discussed Conditions
What conditions are patients discussing?
Most Discussed Symptoms
What symptoms are patients discussing?
What treatments have patients discontinued using?
What treatments are patients switching to?
Top Discussion Forums
What are the most popular websites?